---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-016967"
form_type: "8-K"
ticker: null
cik: "0001835416"
company_name: "Moringa Acquisition Corp"
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T15:41:55.074255+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Moringa Acquisition Corp signs definitive merger with Silexion at $62.5M valuation

## Summary
- SPAC Moringa (MACA) enters Business Combination Agreement with Israeli oncology firm Silexion Therapeutics; pre-transaction equity value $62.5M.
- SPAC sponsor to forfeit 1,567,000 founder shares; closing requires minimum unrestricted cash of $500K.
- Silexion must deliver at least $3.5M in convertible loan financing proceeds by March 10, 2024, as a closing condition.
- Transaction must close by August 19, 2024; no termination fees payable by either party.
- Silexion is a clinical-stage biotech developing therapies for KRAS-mutant solid tumors.

## SEC filing metadata
- accession: 0001213900-24-016967
- form_type: 8-K
- cik: 0001835416
- company_name: Moringa Acquisition Corp
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835416/000121390024016967/0001213900-24-016967-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835416/000121390024016967/ea0200686-8k_moringa.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-016967
- JSON: https://secwatch.observer/filing/0001213900-24-016967.json
- Plain text: https://secwatch.observer/filing/0001213900-24-016967.txt

## Key facts
- Material Agreements
  Moringa Acquisition Corp entered into Business Combination Agreement with Silexion Therapeutics Ltd. valued at $62.5 million (effective 2024-02-21).
  - Action: entry
  - Agreement: merger
  - Counterparty: Silexion Therapeutics Ltd.
  - Value: $62.5 million
  - Effective: 2024-02-21
  source text: On February 21, 2024, Moringa Acquisition Corp, a Cayman Islands exempted company (“ Moringa ”, the “ Company ”, or the “ SPAC ”), together with its wholly-owned Israeli subsidiary (“ Merger Sub ”), entered into a business combination agreement (as the same may be amended, supplemented or otherwise modified from time to time, the “ BCA ”) with Silexion Therapeutics Ltd., an Israeli company (“ Silexion ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835416/000121390024016967/0001213900-24-016967-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.